FARAPULSE, Inc.

FARAPULSE, Inc. is a medical technology company that specializes in advanced cardiac ablation systems using Pulsed Field Ablation (PFA) technology. This innovative approach is designed to treat atrial fibrillation (AF) and other cardiac arrhythmias. FARAPULSE is known for developing the first commercial cardiac PFA system, which has received CE Mark approval in Europe and is FDA-approved in the United States. The technology focuses on non-thermal ablation, allowing for precise targeting of cardiac tissue while minimizing complications and enhancing patient comfort. The core product, the FARAPULSE Pulsed Field Ablation System, utilizes pulsed electrical fields to ablate cardiac tissue safely. It includes the FARAWAVE catheter, which isolates pulmonary veins and posterior walls in patients with AF. FARAPULSE supports healthcare professionals with extensive clinical data, training, and procedural guidance, aiming to improve outcomes for patients who do not respond to medication. The company primarily serves cardiologists and electrophysiologists, as well as hospitals and cardiac care centers involved in catheter ablation procedures.

• Employees 12
• Founded 2012
• Annual Revenue $1500000
• Total Funding $19999173